Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active vitamin D for secondary hyperparathyroidism after bariatric surgery (ActiVitD)
2023-510312-40-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of alfacalcidol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Leiden University Medical Center. Planned start Nov 2024; status: authorised.
02
Drugs
alfacalcidol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on 2023-510312-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510312-40-00.